Scilex Holding's (SCLX) Scilex Bio venture with IPMC said Wednesday it is enrolling patients with Alzheimer's disease showing mild cognitive impairment and mild dementia in the phase 2 study of KDS2010.
The company is currently enrolling 114 subjects in South Korea and enrollment of the US cohort will begin in 2025, Scilex Bio said.
Scilex Bio said it will evaluate the safety and efficacy of the drug in the randomized, double-blind, placebo-controlled study.
IPMC is a representative company of the Bio Innovation Consortium, which holds exclusive rights to NeuroBiogen's KDS2010 global license.
Price: 0.56, Change: -0.01, Percent Change: -2.59
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.